46brooklyn Research reposted this
What does $400 million in kickbacks to PBMs buy you? Higher volumes of OxyContin during the height of the opioid epidemic. An absolute monster of a story on the ugliest side of prescription drug rebates.
46brooklyn Research is an Ohio non-profit corporation whose purpose is to improve the accessibility and usability of U.S. drug pricing data. 46brooklyn takes the myriad drug pricing data sources scattered across the web and stitches them together into data visualizations that can be used by the public to better understand how the drug supply chain functions. 46brooklyn also writes and publishes original research that uses the data within its public data visualizations to shine light on the hidden and complex underbelly of the drug supply chain. At 46brooklyn, we believe the rampant complexity that is characteristic of how our drugs are priced is creating serious consequences for payers, patients, and providers across this country. Our purpose is to unlock the value buried in our country’s vast but disparate drug pricing databases to bring awareness to the nature and design of this complexity. Our hope is that better awareness and education will help improve the accountability of our supply chain and, in time, lead to the much-needed simplification of how drugs are priced. 46brooklyn Research (EIN #83-3213092) is an IRS-recognized 501(c)(3) Public Charity, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your financial advisor if you have more questions.
External link for 46brooklyn Research
Dayton, Ohio, US
46brooklyn Research reposted this
What does $400 million in kickbacks to PBMs buy you? Higher volumes of OxyContin during the height of the opioid epidemic. An absolute monster of a story on the ugliest side of prescription drug rebates.
“You’d assume that employers want to pay less, that they would want to pay more attention… But what I’ve learned is they are often underequipped, underresourced, and oftentimes not understanding the severity of the lack of oversight and accountability.” - Antonio Ciaccia
46brooklyn Research reposted this
🎙Amplifying the voice of Pharmacists & our Profession. Audio branding nerd. Suffering from microphone & corgis fetish. RxPodfather.
In this special episode, we discuss the “Pharmacists Fight Back Act” and explore Ohio's pivotal role in advancing PBM reform. Join us for a compelling discussion with three distinguished pharmacy leaders: David Burke Executive Director of the Ohio Pharmacists Association; Mark Kinney Executive Vice President of Government Relations at the Independent Pharmacy Cooperative (IPC); and Antonio Ciaccia, CEO of 46brooklyn Research & 3Axis Advisors, our resident expert on PBM data. Listen on all #podcast platforms, use the links in the comments, powered by Podbean
“It’s hard to go through the 46brooklyn takedown and conclude that the PBMs are presenting a thoughtful, defensible analysis.”
New drug pricing report: 💊 22 brand list prices went up in August; 1 went down 📈 Enbrel went up 3% 📉 Abrilada solution dropped 62.5% 📊 More generic drugs increased in cost than decreased per NADAC 😎 Rebates are so back Receipts:
“In America, PBMs are supposed to be representing buyers, but they are paid by the sellers through kickbacks. No wonder they want higher prices!” - Matt Stoller
“Health plans and PBMs are often just trying to protect the status quo as it remains today, for obvious reasons, because the environment has benefited them significantly.”
“Just how functional can a market be if there are no actual prices which would appear to govern it?” Our latest on the wide variability in hospital prices for Opdivo:
When seeking answers, we must first judge the merit of the question asked Our latest: Express Scripts vs the FTC https://lnkd.in/gh3Rh53g